Premium
Long‐Term Results of Guided Tissue Regeneration Therapy With Non‐Resorbable and Bioabsorbable Barriers. IV. A Case Series of Infrabony Defects After 10 Years
Author(s) -
Pretzl Bernadette,
Kim TiSun,
Holle Rolf,
Eickholz Peter
Publication year - 2008
Publication title -
journal of periodontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.036
H-Index - 156
eISSN - 1943-3670
pISSN - 0022-3492
DOI - 10.1902/jop.2008.070571
Subject(s) - medicine , dentistry , periodontitis , chronic periodontitis , surgery
Background: A 10‐year follow‐up study was conducted to clinically evaluate the long‐term results after guided tissue regeneration (GTR) therapy of infrabony defects using non‐resorbable and bioabsorbable barriers. Methods: Twelve pairs of contralateral infrabony defects were treated in 12 subjects with advanced periodontitis. Within each subject, one defect received a non‐resorbable barrier and the other received a bioabsorbable barrier by random assignment. Clinical parameters were obtained at baseline and at 12 and 120 ± 6 months after surgery. Results: Eight of 12 subjects were available for the examination at 120 ± 6 months. Twelve and 120 ± 6 months after GTR therapy statistically significant ( P <0.05) vertical clinical attachment level (CAL‐V) gain was observed in both groups (3.4 ± 1.0 mm and 1.5 ± 1.2 mm for the control group at 12 and 120 months, respectively, and 3.3 ± 1.6 mm and 3.5 ± 2.5 mm for the test group at 12 and 120 months, respectively). However, 120 ± 6 months after GTR therapy, three infrabony defects (two controls and one test) had lost >2 mm of the attachment that had been gained 12 months after GTR therapy, and a statistically significant mean CAL‐V loss of 1.7 ± 1.3 mm was observed from 12 to 120 ± 6 months in the control group. One tooth in the control group was lost between 60 and 120 ± 6 months. The case series failed to show statistically significant differences between test and control regarding CAL‐V gain 120 ± 6 months after surgery. Conclusion: CAL‐V gain achieved 12 months after GTR therapy in infrabony defects using non‐resorbable and bioabsorbable barriers was stable after 10 years in 12 of 16 defects.